Back to Search Start Over

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

Authors :
Brian Wynne
Choy Y. Man
Daisy J. Brandon
Andrea Antinori
Jose R. Arribas
Pedro Cahn
Pierre-Marie Girard
Mark R. Underwood
Kimberly Y. Smith
Amanda Clarke
Juan Sierra Madero
Jean van Wyk
Jörg Sievers
Martin Gartland
Rimgaile Urbaityte
Michael Aboud
Keith A. Pappa
Chien-Ching Hung
Allan R Tenorio
Roberto Ortiz
Jürgen K. Rockstroh
Source :
Journal of acquired immune deficiency syndromes (1999). 83(3)
Publication Year :
2019

Abstract

Two-drug regimens (2DRs) can potentially reduce long-term cumulative drug exposure and decrease treatment-associated costs for HIV-1–infected individuals, who require lifelong therapy.1 The core antiretroviral agent in a 2DR must have high potency and a high barrier to resistance.1 As such, early studies investigating 2DRs as initial or maintenance therapy for HIV infection evaluated the pairing of the potent, well-tolerated nucleoside reverse transcriptase inhibitor (NRTI) lamivudine with pharmacologically boosted protease inhibitors (PIs), which have a high barrier to resistance.2–6 Although noninferior efficacy was shown against 3-drug regimens (3DRs), PIs are associated with adverse metabolic effects, long-term toxicities, and drug–drug interactions, limiting their appeal as components of lifelong therapy.7,8 Thus, a need remains for well-tolerated, potent 2DRs with a high barrier to resistance. The integrase strand transfer inhibitor (INSTI) dolutegravir has a high barrier to resistance, making it a well-suited candidate for inclusion in a 2DR,9 particularly when paired with lamivudine,10 as previously observed.11,12 In primary week 48 analyses of the 2 phase III studies GEMINI-1 and GEMINI-2 in treatment-naive adults, dolutegravir + lamivudine was noninferior to dolutegravir + tenofovir disoproxil fumarate/emtricitabine in achieving HIV-1 RNA

Details

ISSN :
19447884
Volume :
83
Issue :
3
Database :
OpenAIRE
Journal :
Journal of acquired immune deficiency syndromes (1999)
Accession number :
edsair.doi.dedup.....e12488d59ced9e7aed80902e5e729b9d